Capital Bluecross cardiac hemodynamic monitoring Coverage

Coverage Criteria and Policy Stance

Overall coverage stance

Covered only when supported by evidence or per device-specific approvals; otherwise investigational in the ambulatory/outpatient setting.

Investigational devices: In the ambulatory care and outpatient setting, cardiac hemodynamic monitoring using implantable direct pulmonary artery pressure monitoring, thoracic bioimpedance, inert gas rebreathing, and arterial pressure during the Valsalva maneuver is considered investigational.

Insufficient evidence to support a general conclusion concerning health outcomes or benefits.

Implantable PA sensor evidence summary (CardioMEMS and Cordella)

Evidence and outcomes considered for implantable PA sensors in NYHA II–IV patients with prior hospitalization and/or elevated natriuretic peptides.

Key evidence points: Randomized trials, meta-analyses, and nonrandomized studies exist for implantable pulmonary artery pressure sensors (notably CardioMEMS; Cordella evidence limited to single-arm studies). The CHAMPION RCT reported a 28% reduction in heart failure hospitalization; GUIDE-HF did not meet its primary endpoint overall but a pre–COVID-19 subgroup analysis reported a 19% reduction in the primary endpoint driven by a 28% HFH reduction; MONITOR-HF showed improved KCCQ and reduced HFH but no mortality benefit. Safety concerns include potential higher procedural complications (pulmonary artery injury) and limited periprocedural safety data for some devices.

Benefits are primarily on hospitalization outcomes; uncertainties include potential bias from nurse interventions, COVID-19 impact on GUIDE-HF, and limited randomized evidence for some systems.

Implantable pulmonary artery pressure sensors

Summary of evidence-based coverage stance and key findings for implantable pulmonary artery pressure sensors.

Implantable pulmonary artery pressure monitoring (CardioMEMS/Cordella): Evidence demonstrates reductions in heart failure hospitalizations in several analyses (e.g., CHAMPION; GUIDE-HF pre–COVID analysis with 28% HFH reduction) and improvements in some quality-of-life measures (MONITOR-HF; secondary endpoints in PROACTIVE-HF). However, overall evidence is conflicted regarding mortality and functional outcomes, periprocedural safety data are limited for some devices, and net health benefit remains uncertain.

Ongoing trials (open access GUIDE-HF phase, PROACTIVE-HF, PASSPORT-HF) may further clarify benefits.

Nonimplantable hemodynamic monitoring modalities

Nonimplantable or alternative hemodynamic monitoring modalities and the policy conclusions about them.

Thoracic bioimpedance monitoring: Evidence is limited to uncontrolled prospective studies and case series; there is a lack of randomized controlled trial evidence and insufficient data to determine improvement in net health outcomes.

Inert gas rebreathing: No studies identified on clinical validity or clinical utility for outpatient hemodynamic monitoring with inert gas rebreathing; evidence is insufficient to determine improvement in net health outcomes.

Investigational when used in ambulatory/outpatient setting per policy.

Valsalva maneuver arterial pressure monitoring: A single study reported 85% sensitivity and 80% specificity for detecting LVEDP > 15 mm Hg, but evidence is insufficient to determine that this monitoring approach improves net health outcomes.LVEDP > 15 mm Hg

This policy applies only to stand-alone cardiac output measurement devices designed for use in ambulatory care and outpatient settings. Devices that are integrated into other implanted cardiac systems or used in inpatient/acute settings are outside the scope of this policy and are not addressed here.

Procedure and HCPCS codes identified in the coding section as investigational are excluded from coverage when used for ambulatory/outpatient hemodynamic monitoring. Examples called investigational in the policy include procedure codes such as 93701, 0608T, 0933T, 0934T, C2624, G0555, 33289, 93050, 93264, and the separately noted code 93799 when used for inert gas rebreathing in the outpatient setting. Identification of a code in the coding section does not itself denote coverage and claims may be denied based on member benefits and the investigational status of the service.

Within the provided excerpt there are no additional explicit policy exclusions beyond the scope limitation to stand-alone outpatient cardiac output devices and the investigational coding exclusions noted elsewhere in the policy.

For outpatient use, cardiac hemodynamic monitoring methods described in this policy (implantable pulmonary artery pressure monitoring, thoracic bioimpedance, inert gas rebreathing, and arterial pressure measurement during the Valsalva maneuver) are considered investigational due to insufficient evidence to support improved net health outcomes. The policy specifically states these modalities are investigational in the ambulatory care and outpatient setting.

The rationale for the investigational stance includes conflicting evidence regarding mortality and functional outcomes (for example, mixed results across CHAMPION, GUIDE-HF, and MONITOR-HF analyses), limited randomized controlled trial data for some devices, and limited periprocedural safety data for certain systems. For nonimplantable modalities, the evidence is sparse or absent (no clinical validity or utility studies identified for inert gas rebreathing), and single-study or uncontrolled series dominate the literature for thoracic bioimpedance and Valsalva-based methods, leaving uncertainty about clinical benefit.

The policy excerpt does not include explicit statements phrased as 'not medically necessary.' References, background, and rationale material are provided, along with a coding and policy history, but no discrete 'not medically necessary' declaration appears in the supplied chunks.

Regulatory Codes, Billing, and Procedure Codes

Regulatory/product codes and devicesmixed

FDA product code: DXN	VeriCor noninvasive LVEDP device
FDA product code: DSB	Thoracic impedance plethysmography devices (representative list)
FDA product code: BZG	Inert gas rebreathing device (Innocor)
CardioMEMS, Cordella	Implantable pulmonary artery pressure sensor systems (PMAs)

Investigational procedure codes (listed separately)CPTNot Covered

93799

Procedure code — investigational when used for ambulatory care and outpatient inert gas rebreathing

Investigational / Not covered codes (policy list)mixedNot Covered

93701	Procedure code (listed as investigational in policy text)
0608T	Procedure code (listed as investigational in policy text)
0933T	Procedure code (listed as investigational in policy text)
0934T	Procedure code (listed as investigational in policy text)
C2624	HCPCS code (listed as investigational in policy text)
G0555	HCPCS code (listed as investigational in policy text)
33289	Procedure code (listed as investigational in policy text)
93050	Procedure code (listed as investigational in policy text)
93264	Procedure code (listed as investigational in policy text)

Policy history code changesmixed

C9728	code added (document notes)
0607T	code added (document notes)
0608T	code added (document notes)
C9758	code removed (document notes)
0933T	code added (12/11/2024 administrative update)
0934T	code added (12/11/2024 administrative update)
G0555	code added (12/11/2024 administrative update)

LVEDP detection threshold

LVEDP detection threshold> 15 mm Hg

Reported diagnostic performance85% sensitivity for LVEDP >15 mm Hg

Reported diagnostic performance80% specificity for LVEDP >15 mm Hg

Provider Requirements, Prior Authorization, and Billing Guidance

Prior Authorization

Prior Authorization / Product Variations

Prior authorization requirements vary by product and program administered by Capital Blue Cross. Providers must verify member benefits and prior authorization rules for the specific product (including FEP PPO and other benefit variations) before providing services.

Prior authorization may be required for certain products — check member benefit plan.
Providers should contact Capital Blue Cross Provider Services or Member Services to verify benefits and authorization requirements.

Documentation Required

Documentation and Benefit Verification

Providers must document medical necessity for cardiac hemodynamic monitoring devices and related services in the outpatient/ambulatory setting. Documentation should support the clinical indication and that conservative management was attempted when appropriate.

Document clinical rationale and prior conservative management when applicable.

Clinical Background and Evidence Context

Patients with chronic heart failure are at ongoing risk for acute decompensation and hospitalization. Early identification of physiologic changes through hemodynamic monitoring could enable earlier intervention (for example, medication adjustment or intensified outpatient management) to prevent admissions. Standard inpatient hemodynamic assessment uses pulmonary artery catheters, but outpatient approaches (implantable PA sensors or noninvasive techniques) aim to provide serial physiologic data to guide treatment and potentially reduce heart failure hospitalizations.

Definitions and Key Terms

Cardiac hemodynamic monitoring (outpatient) — device/technique list

Implantable PA pressure sensorsImplanted sensor placed in pulmonary artery that transmits PA pressure measurements for clinician review (e.g., CardioMEMS, Cordella)

Thoracic bioimpedance devicesNoninvasive thoracic impedance measurement devices intended to estimate fluid status and cardiac output in outpatient settings

Inert gas rebreathing devicesNoninvasive devices using inert gas rebreathing (e.g., Innocor) to estimate cardiac output

Arterial waveform during Valsalva maneuverMeasurement of arterial pressure changes during Valsalva to infer left ventricular filling pressures

Implantable pulmonary artery (PA) pressure sensor definition

DefinitionAn implanted sensor placed in the pulmonary artery that transmits PA pressure measurements to a secure database for clinician review (examples: CardioMEMS, Cordella)

OpenPayer

Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting

Coverage Criteria and Policy Stance

Regulatory Codes, Billing, and Procedure Codes

Provider Requirements, Prior Authorization, and Billing Guidance

Clinical Background and Evidence Context

Definitions and Key Terms